Fulcrum Therapeutics (NASDAQ: FULC) revenue
Fulcrum Therapeutics reported revenue of $0.0m for fiscal 2025, 100.0% less than in fiscal 2024 ($80.0m).
Fulcrum Therapeutics's best year of the last 6 was fiscal 2024. The biggest drop was in fiscal 2022, −66.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $0.0m | −100.0% | −$84.8m | — |
| 2024 | $80.0m | +2,752.0% | −$21.9m | −27.4% |
| 2023 | $2.8m | −55.8% | −$110.7m | −3,945.2% |
| 2022 | $6.3m | −66.9% | −$112.6m | −1,774.9% |
| 2021 | $19.2m | +117.2% | −$81.1m | −423.0% |
| 2020 | $8.8m | — | −$71.6m | −811.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Fulcrum Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Fulcrum Therapeutics ranks 409th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Fulcrum Therapeutics, −100.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 407th | Denali Therapeutics | $0.0m | — |
| 408th | Design Therapeutics | $0.0m | — |
| 409th | Fulcrum Therapeutics | $0.0m | −100.0% |
| 410th | Monopar Therapeutics | $0.0m | — |
| 411th | Neurogene | $0.0m | −100.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Fulcrum Therapeutics
- How much revenue did Fulcrum Therapeutics make in fiscal 2025?
- Fulcrum Therapeutics reported revenue of $0.0m for fiscal 2025, compared with $80.0m in fiscal 2024.
- What was the best year for revenue at Fulcrum Therapeutics?
- Of its last 6 fiscal years, fiscal 2024, with $80.0m.
- Where does Fulcrum Therapeutics rank in its sector by revenue?
- It ranks 409th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Fulcrum Therapeutics come from?
- From the annual report (Form 10-K) that Fulcrum Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Fulcrum Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Fulcrum Therapeutics: the Fulcrum Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.